Parallel to the "poppy-seed defense" strategy commonly reported in the United States, donors of urine samples tested positive for opiates in Taiwan often claimed the consumption of Brown Mixture (BM) as the source of the observed morphine and codeine. Because BM contains opium powder (10.0-10.5% morphine), opium tincture (0.9-1.1% morphine), or camphorated opium tincture (0.045-0.055 % morphine) and is a popular remedy, and heroin use is considered a serious criminal act, the claim of BM use has to be adequately addressed. In this study, 8M from seven different manufacturers (5 tablets and 2 solutions) and urine samples from alleged heroin users and volunteers with various ingestion patterns and were analyzed for their morphine and codeine contents. The analytical procedure included hydrolysis, trimethylsUylation, and gas chromatography-mass spectrometry analysis. The contents of morphine and codeine in the tablets were found to be very consislenl, but with significant differences in the two BM solutions. Morphine concentrations found in urine specimens collected from volunteers ingesting BM tablets (or solutions) were always < 4000 ng/mL. ]'he following morphine-to-codeine ([M]/[C]) ratios were observed for urine specimens with morphine concentration > 300 ng/mL: (A) < 3.0 for volunteers ingesting BM solution and (B) > 3.0 (mostly > 5.0) for volunteers ingesting BM tablets and alleged heroin users. It appeared that (A) BM ingestion (tablet or solution) was unlikely to result in a morphine concentration > 4000 ng/mL; and (B) Parallel to the "poppy-seed defense" strategy (1-3) commonly reported in the United States, donors of urine samples tested positive for opiates in Taiwan often claimed the consumption of Brown Mixture (BM) I as the source of the observed morphine and codeine. Because BM contains opium powder (10.0-t0.5% morphine) (4), opium tincture (0.9-1.1% morphine) (4), or camphorated opium tincture (0.045-0.055% morphine) (4) and is a popular cold remedy, and heroin use is considered a serious criminal act in Taiwan, the claim of BM use has to be adequately addressed. Although the presence of 6-monoacetylmorphine is an indication of heroin exposure (1), the half-life of this heroin metabotite is relatively short (5); thus, the presence/absence of this metabolite may not always be an effective criterion for differentiating samples derived from heroin users from those ingesting other opiates-containing materials.
Parallel to the "poppy-seed defense" strategy (1-3) commonly reported in the United States, donors of urine samples tested positive for opiates in Taiwan often claimed the consumption of Brown Mixture (BM) I as the source of the observed morphine and codeine. Because BM contains opium powder (10.0-t0.5% morphine) (4), opium tincture (0.9-1.1% morphine) (4), or camphorated opium tincture (0.045-0.055% morphine) (4) and is a popular cold remedy, and heroin use is considered a serious criminal act in Taiwan, the claim of BM use has to be adequately addressed. Although the presence of 6-monoacetylmorphine is an indication of heroin exposure (1), the half-life of this heroin metabotite is relatively short (5); thus, the presence/absence of this metabolite may not always be an effective criterion for differentiating samples derived from heroin users from those ingesting other opiates-containing materials.
With this in mind, the authors conducted a study to investigate the characteristics of urine samples collected from volunteers who have received oral doses of BM. The morphine-tocodeine ([M]/[C]) ratio and their concentration levels in these samples were compared with those from alleged heroin abuse cases. It was hoped that these parameters (6) might help confirm non-heroin use. In this study, BM from seven different manufacturers (5 tablets and 2 solutions--all that are available in Taiwan) and urine samples from volunteers and alleged heroin users were analyzed for their morphine and codeine contents. 
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Materials and Methods

Chemicals and reagents
All solvents and reagents were high-performance liquid chromatography grade and purchased from J.T. Baker Chemical Corporation (Phillipsburg, N J). N-Methyl-N-trimethylsilyltrifluoroacetamide (MSTFA) was obtained from Sigma Aldrich Chemical Corporation (Milwaukee, WI). Codeine, morphine, and nalorphine solutions (1.0 mg/mL in methanol) were provided by Cerilliant Corporation (Austin, TX). Urine confirmed negative by GC-MS was used to prepare standards and controls.
BM intake and urine collection
All protocols related to the administration of BM to seven volunteers have been approved by the IRB of the Taipei Medical University.
Single-dose study. Four volunteers were administered a single oral dose of 1, 2, 4, and 6 tablets of BM, respectively. Two weeks after the completion of the first experiment, the same four volunteers were again administered a single oral dose of 5, 10, 15, and 20 mL of BM solution, respectively.
Multiple-dose study. Three volunteers were administered multiple oral doses (three times per day for two days) of 1, 2, and 4 tablets of BM, respectively. Two weeks after the completion of the first experiment, the same three volunteers were again administered multiple oral doses of 5, 10, and 15 mL of BM solution, respectively.
Urine collection. Urine was collected at 0, 2, 4, 6, 8, 10, 12, 14, and 16 h, after which it was collected every 4 or 8 h until both codeine and morphine became undetectable (< 0.05 pg/mL). The volumes of all specimen collections were recorded.
Ninety urine samples from alleged heroin abusers were also used for this study. 
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Concentration (ng/mL) Figure 2 . Calibration curves plot for codeine (A) and morphine (B) each in urine fortified at concentrations of 50, 125, 250, 500, 1000, and 1500 ng/mL.
Fluorescence polarization immunoassay
All urine samples were first screened by TDx Fluorescence Polarization Immunoassay without pretreatment. Reagent packs, calibrators, controls, and buffer solutions were obtained from Abbott Laboratories. All calibration and test procedures were performed automatically and according to the assay parameters specified by the manufacturer. Calculations were automatically performed and numerical results were printed by the TDx Analyzer (7).
Sample preparation
BM tablets or solution. For the analysis of morphine and codeine compositions in BM tablet, 10 mL 0.5N HC1 was added to a screw-capped glass tube containing one BM tablet and mixed by sonication for 30 min. One milliliter of the mixture was then transferred to a 25-mL volumetric flask, then filled to 25 mL with deionized water and thoroughly mixed. For the analysis of BM solutions, 1 mL BM solution was transferred to a 50-mL volumetric flask, then filled to 50 mL with deionized water and thoroughly mixed.
Hydrolysis and extraction of urine and BM mixture solution. Each sample (2 mL urine or BM mixture solution prepared as described previously) was spiked with 50 IJL of nalorphine internal standard (10 IJg/mL), followed by the addition of 1 mL 6N HC1. The acidified urine or BM mixture solution was hydrolyzed in a dry-bath at 120~ for 1 h. The mixture was cooled to room temperature and extracted with 5 mL 4:1 (v/v) dichloromethane/isopropanol. The aqueous layer was transferred and made basic with 0.47 mL 13N NaOH and I mL Na2CO3/NaHCO3 buffer (pH 9.5) and extracted with 5 mL 4:1 (v/v) dichloromethane/isopropanol. The mixture was then centrifuged and the aqueous layer aspirated. The organic extract was transferred to a clean screw-top tube and evaporated to dryness under a stream of nitrogen at 50~
Preparation of trimethylsilyl derivatives. For derivatization, 501JL ethyl acetate and 50 ]JL MSTFA were added to the residue in the screw-top tube prepared previously. The capped tube was vortex mixed for 20 s and then heated at 100~ for 15 min. The reaction mixture was allowed to cool to room temperature prior to gas chromatography-mass spectrometry (GC-MS) analysis.
GC-MS
An Agilent 6890N GC/5973N mass selective detector, operated at 70 eV with ion source temperature of 230~ was used in this study. The GC was equipped with a 30-m Hewlett-Packard (Andover, MA) HP-1MS fused-silica capillary column (0.25-ram i.d., 0.25-1Jm film thickness). The injector and interface temperature were maintained at 260~ and 280~ respectively. The inlet pressure was held at 5 psi for I rain, then programmed to 20 psi at 2 psi/rain, and held for 6.5 min. Oven temperature was held at 120~ for 1 min, then programmed to 280~ at 20~ and held at the final temperature for 6 rain. The following parameters were used for injecting samples into the GC-MS system: sample size, 1 ]JL; injection mode, splitless; and injector purge-off duration, i rain.
Ions selected for monitoring the resulting TMS-derivatives were m/z 371, 356, and 343 for codeine; 429, 414, and 401 for morphine; and 455, 440, and 414 for nalorphine. The first ion listed for each compound was used for quantitation using a six-point (50, 125, 250, 500, 1000, and 1500 ng/mL) calibration protocol. 
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Results and Discussion
Analytical parameters
The overall protocol was fully evaluated, and the following analytical parameters were established: excellent linearity within the 50-1500 ng/mL range studied; intraday and interday precisions ranging from 0.99% to 3.51% for codeine and 1.06% to 6.56% for morphine; limits of detection and quantitation of 10 and 30 ng/mL for morphine and 15 and 40 ng/mL for codeine, respectively; and overall recoveries for total codeine and total morphine of 94.8% and 88.4%, respectively. Mass spectra of TMS-derivaTime of tized codeine, morphine, and nalorphine Dosing are shown in Figure 1 . Calibration curves (h) are demonstrated by the concentration versus peak response ratio plots shown in o Figure 2 .
Morphine and codeine content of BM
Result derived from the analysis of five BM tablets and two BM solutions from different manufacturers are shown in Table I Because codeine is not a metabolite of morphine (5, 8, 9) , though codeine can be converted to morphine via demethylation by human metabolism, it is anticipated that the [M]/[C] ratio observed in the urine samples collected from a heroin user will be higher than that from a BM solutions user.
Codeine and morphine excretion characteristics following BM ingestion
Urinary excretion of codeine and morphine (and their ratios Table II indicate morphine concentrations in urine collected from volunteers with a single dose of 4 or fewer BM tablets were less than 2000 ng/mL. When 6 tablets were ingested, it was likely that the morphine concentration exceeded 2000 ng/mL. The highest excretion of opiates occurred at 2-6 h following BM tablets ingestion.
[M]/[C] ratios ranged from 4.98 to 14.82 with 10.11 as the mean and 3.31 as the standard deviation. With the ingestion of 1, 2, 4, and 6 tablets, the times necessary for the concentration of morphine to become < 300 ng/mL were 6, 10, 10, and 16 h, respectively.
Data shown in Table III indicate that, when four or fewer tablets were taken, morphine concentrations in urine samples collected from multiple doses (three times per day for 2 days) of BM tablets were less than 3000 ng/mL. [M]/[C] ratios in these samples ranged from 4.88 to 13.35, with a mean of 7.08 (standard deviation = 1.56). Depending on the number of tablets taken, it took 12-20 h for the concentration of morphine to drop to < 300 ng/mL. The concentration of codeine and morphine following the ingestion 2 tablets of BM derived from GC-MS analysis are plotted in Figure 3 .
Data resulting from samples collected from volunteers talking single and multiple doses of BM solutions are shown in Tables IV and V indicate morphine concentrations in urine collected following single and multiple doses of BM solution were most likely < 4000 ng/mL. The highest excretion rate of opiates occurred at 2-4 h following ingestion of a single dose of BM solution. The concentration of codeine and morphine following the ingestion 10 mL of BM solutions derived from GC-MS analysis are plotted in Figure 4 . Table VI lists 
Conclusions
found to be very consistent, but with significant differences in the two BM solutions studied. Morphine concentrations found in urine specimens collected from volunteers ingesting BM tablets or solutions were always < 4000 ng/mL. The following [M]/[C] ratios were observed for urine specimens with morphine concentrations > 300 ng/mL: (A) < 3.0 for volunteers ingesting BM solution and (g) > 3.0 (mostly > 5.0) for volunteers ingesting BM tablets and alleged heroin users. It appeared that (A) BM ingestion (tablet or solution) was unlikely to result in a morphine concentration > 4000 ng/mL and (B) [M]/[C] ratio might not be an effective parameter for the differentiation of BM tablet ingestion and heroin use.
